NeuroMetrix, Inc. - Common Stock (NURO)
Frequently Asked Questions About NeuroMetrix, Inc. - Common Stock (NURO)
Are there any side effects associated with NeuroMetrix products?
While many users find relief through NeuroMetrix products like Quell, some may experience mild skin irritation or discomfort at the site of electrode placement. It’s important for users to follow the instructions provided and consult with their healthcare providers if they have any concerns or pre-existing conditions that may affect their usage.
Does NeuroMetrix have any partnerships?
NeuroMetrix has formed various partnerships within the healthcare sector to enhance its product offerings and reach. These collaborations often include healthcare providers, research institutions, and technology companies aimed at advancing the company’s mission to develop effective solutions for chronic pain and related conditions.
How can I purchase NeuroMetrix products?
NeuroMetrix products, such as Quell and DPNCheck, can be purchased through various channels including the official NeuroMetrix website and select medical supply retailers. Additionally, healthcare providers may offer these products in clinical settings, allowing for integrated treatment options for patients.
How does NeuroMetrix contribute to healthcare research?
NeuroMetrix contributes to healthcare research by collaborating with academic institutions, hospitals, and clinical researchers to conduct studies that evaluate the effectiveness of its products. The company actively participates in clinical trials and publishes findings in medical journals, promoting evidence-based practices for pain management and diabetic health.
How does NeuroMetrix engage with its customers?
NeuroMetrix engages with its customers through various channels, including customer support services, educational resources, and feedback mechanisms. The company aims to foster strong relationships with both patients and healthcare providers by providing comprehensive information, support for product usage, and avenues for customer feedback to continuously enhance their offerings.
How does Quell work?
Quell is a wearable device that uses transcutaneous electrical nerve stimulation (TENS) technology to provide pain relief. It works by delivering stimulating pulses through the skin to activate the body’s natural pain relief systems, reducing the perception of pain and providing comfort. The device is designed for use on a variety of pain types and is adjustable based on individual needs.
Is NeuroMetrix publicly traded?
Yes, NeuroMetrix, Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol NURO. The company went public to raise capital for its innovative health technologies and to allow investors to participate in its growth and development.
What are the future plans for NeuroMetrix?
NeuroMetrix plans to continue advancing its research and development efforts to expand its product portfolio and enhance existing solutions. The company aims to explore new market opportunities, contribute to clinical research, and strengthen partnerships to drive innovation in pain management and neurological health.
What are the key benefits of using Quell?
Quell offers several benefits including non-invasive pain relief, the ability to customize therapy settings, and portability for use throughout daily activities. Users can also track their pain relief and therapy usage through a mobile app, providing an integrated approach to managing chronic pain effectively.
What are the main products offered by NeuroMetrix?
NeuroMetrix primarily offers a range of products including Quell, a wearable pain relief device that uses neuromodulation technology to manage chronic pain, and DPNCheck, a device designed for the assessment of diabetic peripheral neuropathy. These products are aimed at improving patient quality of life through advanced technology solutions that provide effective management of symptoms and conditions.
What clinical evidence supports NeuroMetrix's products?
NeuroMetrix's products, particularly Quell and DPNCheck, are supported by a body of clinical evidence demonstrating their effectiveness in managing chronic pain and diagnosing diabetic peripheral neuropathy. Studies published in peer-reviewed medical journals highlight the positive outcomes and benefits associated with the use of these devices, adding credibility to their clinical applications.
What does NeuroMetrix, Inc. do?
NeuroMetrix, Inc. is a health technology company that develops and commercializes innovative medical devices and therapies for chronic pain, neurological disorders, and diabetes. The company focuses on delivering non-invasive diagnostic and therapeutic solutions that leverage proprietary technologies in neurostimulation and digital health, aiming to enhance patient diagnosis and improve overall treatment outcomes.
What is DPNCheck and how is it used?
DPNCheck is a diagnostic device developed by NeuroMetrix to assess diabetic peripheral neuropathy (DPN) in patients with diabetes. It utilizes a quick and convenient non-invasive methodology to test sensory nerve function in the feet and provides immediate results, helping healthcare providers in the early diagnosis and management of DPN.
What is the company's mission statement?
NeuroMetrix's mission is to improve the quality of life for patients suffering from chronic pain and neurological conditions through innovative technologies. The company is committed to producing effective, clinically validated solutions that empower patients and healthcare providers in their pain management and healthcare journeys.
What is the impact of NeuroMetrix on chronic pain management?
NeuroMetrix has made a significant impact on chronic pain management by offering non-invasive, drug-free solutions that empower patients to take control of their pain. Through devices like Quell, patients can manage their symptoms more effectively, reducing reliance on medications and improving their overall quality of life.
What is the target market for NeuroMetrix's products?
NeuroMetrix targets several key markets with its products, including individuals suffering from chronic pain, healthcare providers, and patients with diabetes. The company’s solutions are designed for both consumers and clinicians, addressing the growing demand for effective, non-invasive treatment options in pain management and neurological health.
What regulatory approvals has NeuroMetrix obtained?
NeuroMetrix has received regulatory approvals for its products from the U.S. Food and Drug Administration (FDA), including 510(k) clearances for Quell and DPNCheck. These approvals signify that the products meet established safety and efficacy standards, allowing them to be marketed and sold to healthcare professionals and consumers in the United States.
When was NeuroMetrix founded?
NeuroMetrix was founded in 1996 by Dr. Shai N. Gozani, who aimed to innovate in the field of neurodiagnostics and therapeutic technologies. The company has since grown and evolved, focusing on developing solutions for chronic pain management and diabetic complications through advanced medical devices.
Where is NeuroMetrix headquartered?
NeuroMetrix, Inc. is headquartered in Woburn, Massachusetts. This location serves as the central hub for the company's research and development activities, corporate operations, and strategic initiatives that drive the innovation of its products.
What is the current price of NeuroMetrix, Inc. - Common Stock?
The current price of NeuroMetrix, Inc. - Common Stock is 4.420
When was NeuroMetrix, Inc. - Common Stock last traded?
The last trade of NeuroMetrix, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of NeuroMetrix, Inc. - Common Stock?
The market capitalization of NeuroMetrix, Inc. - Common Stock is 9.10M
How many shares of NeuroMetrix, Inc. - Common Stock are outstanding?
NeuroMetrix, Inc. - Common Stock has 2.06M shares outstanding.